ColonFlag Assists with Diagnostic Decision-making, Based on Applying Advanced AI to Existing EHR Data
KFAR MALAL, Israel – June 27, 2017 – Medial EarlySign (earlysign.com), a developer of machine learning tools for data driven medicine, today announced a strategic collaboration with Medicover, a leading international healthcare and diagnostic services provider, to identify individuals at high risk of harboring colorectal cancer (CRC).*
Medicover, one of Poland’s largest private healthcare providers, selected Medial EarlySign’s ColonFlag tool for a pilot project after learning of its scientific retrospective analysis and validation for identifying individuals that should be tested for disease. ColonFlag applies advanced AI and machine learning algorithms to large amounts of ordinary medical data, such as total blood test results and other EHR data, flagging high-risk individuals for further evaluation.
“Colorectal cancer is the second most common cancer in Poland in women and third most common in men. It is the fourth cause of death due to neoplastic diseases. In Poland an average five-year survival rate is slightly under 50%. If an early stage colorectal cancer is diagnosed, the 5-year survival rate can be even higher than 90%,” said Dr. Bożena Walewska-Zielecka, Medical Director for Medicover. “Early detection is paramount to the effective treatment of CRC, and ColonFlag can provide the ability to better identify patients with increased cancer risk, resulting in more targeted referrals for colonoscopies and significantly improved outcomes.”
The pilot will determine the most effective process to implement a workflow to identify patients at risk of increased risk of colorectal cancer. The success of the pilot could result in Medicover adding ColonFlag to its routine diagnostic process.
“We are pleased to collaborate with Medicover in its first implementation of machine learning algorithms to enhance the diagnostic decision-making process,” said Ori Geva, CEO of Medial EarlySign. “These are the first steps of integrating a technology that will have a far-reaching impact in supplying physicians and healthcare providers with predictive tools to provide personalized care for high-risk patients.”
In addition to its work with Medicover, Medial EarlySign is currently conducting clinical studies with more than 20 million patients in 14 institutions around the world.
*Note: ColonFlag bears the CE marking to aid in identifying individuals of the general population at increased risk of colorectal cancer for whom further evaluation is recommended.
ColonFlag is not available for sale in the US.
# # #